Trial · NCT07173127
The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters
NCT07173127, Not applicable, Recruiting, University Hospital, Geneva
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters. Trials, record NCT07173127. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07173127
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters
- NCT number
- NCT07173127
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- University Hospital, Geneva
- Conditions
- Uterine Fibroid
- Interventions
- Ryeqo treatment
- First posted
- 2025-09-15
- Last updated
- 2026-04-29
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in the mean value of normalized activated protein C resistance (nAPCsr) at 3 months of treatment with Ryeqo | At baseline and after 3 months of treatment | Blood dosage of normalized activated protein C resistance (nAPCsr) |
| Secondary | Mean change from baseline to 3 months of treament in the value of sexual hormone-binding globulin (SHBG) | At baseline and after 3 months of treatment | Mean value of SHBG as expressed in nmol/l units |
| Secondary | Mean change from baseline to 3 months of treament in the value of normalized thrombomodulin sensitivity ratios (nTMSR) | At baseline and after 3 months of treatment | Mean value of nTMSR as expressed as ratio |
| Secondary | Mean change from baseline to 3 months of treament in the value of D-Dimers | At baseline and after 3 months of treatment | Mean value of D-dimers as expressed with ng/ml units |
| Secondary | Mean change from baseline to 3 months of treament in the value of thrombin generation markers | At baseline and after 3 months of treatment | Mean value of thrombin generation markers, such as : thrombin generation markers * endogenous thrombin potential (ETP), expressed in nMxmin * peak value, expressed in nM * time to peak, expressed in min * lag time, expressed in min |
| Secondary | Mean change from baseline to 3 months of treament in the value of antithrombin activity | At baseline and after 3 months of treatment | Mean change in antithrombin activity, expressed as a percentage |
| Secondary | Mean change from baseline to 3 months of treament in the value of Tissue factor pathway inhibitor (TFPI) | At baseline and after 3 months of treatment | Mean change in the value of TFPI, as expressed in ng/ml |
| Secondary | Mean change from baseline to 3 months of treament in the value of fibrinogen | At baseline and after 3 months of treatment | Mean change in the value of fibrinogen, as expressed in g/l |
| Secondary | Mean change from baseline to 3 months of treament in the value of free protein S | At baseline and after 3 months of treatment | Mean change in the value of free protein S, expressed as a percentage |
| Secondary | Mean change from baseline to 3 months of treament in the value of factor VIII concentration | At baseline and after 3 months of treatment | Mean change in the value of factor VIII concentration, expressed as a percentage |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37939264 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07173127
GET https://conductscience.org/api/trials/v1/NCT07173127/registered